The Australian Rheumatology Association (ARA) has labelled an upcoming government-funded, industry-driven biosimilars initiative for clinicians as ‘promotional’ rather than educational. The ARA’s Biosimilars Working Group Co-chair Dr Mona Marabani told the limbic that its advice to rheumatologists around the Generic and Biosimilar Medicines Association (GBMA) Biosimilars Week “was what we would give to any member when ...
We don’t need no ‘education’: ARA takes aim at biosimilar ‘promotion’
By David Rowley
2 Apr 2019